Media coverage about Merrimack Pharmaceuticals (NASDAQ:MACK) has trended somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Merrimack Pharmaceuticals earned a news impact score of 0.09 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.80310770758 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Shares of Merrimack Pharmaceuticals (NASDAQ MACK) traded up $0.10 during mid-day trading on Friday, hitting $11.75. 86,412 shares of the stock were exchanged, compared to its average volume of 175,138. The company has a current ratio of 3.35, a quick ratio of 3.35 and a debt-to-equity ratio of 0.45. Merrimack Pharmaceuticals has a 12 month low of $11.14 and a 12 month high of $65.90.

A number of brokerages have recently issued reports on MACK. Robert W. Baird reaffirmed a “hold” rating and issued a $15.00 target price on shares of Merrimack Pharmaceuticals in a report on Friday, October 13th. ValuEngine cut shares of Merrimack Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Monday, October 2nd. Finally, Zacks Investment Research cut shares of Merrimack Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $61.80.

WARNING: “Merrimack Pharmaceuticals (MACK) Given News Sentiment Score of 0.09” was published by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at

In other Merrimack Pharmaceuticals news, Director Ulrik B. Nielsen sold 21,556 shares of the stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $14.40, for a total value of $310,406.40. Following the transaction, the director now directly owns 37,437 shares of the company’s stock, valued at approximately $539,092.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Ulrik B. Nielsen sold 7,896 shares of the stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $14.23, for a total transaction of $112,360.08. Following the completion of the transaction, the director now directly owns 22,781 shares in the company, valued at $324,173.63. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 44,308 shares of company stock worth $637,558. 8.53% of the stock is owned by insiders.

About Merrimack Pharmaceuticals

Merrimack Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development.

Insider Buying and Selling by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)

Receive News & Ratings for Merrimack Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.